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Abstract
Streptococcus pneumoniae is the main causative agent of
pneumonia, with a 10 to 25 percent rate of isolation in blood
cultures. Controversies exist regarding the prognostic impact
of a history of human immunodeficiency virus (HIV) infection
on community-acquired pneumonia.
The aim of our work was to analyze and compare the clinical
presentation, radiological findings and progression of pneu-
mococcal pneumonia in patients infected with and not in-
fected with HIV. We retrospectively analyzed adult patients
with positive blood cultures for Streptococcus pneumoniae
and clinical and radiological findings compatible with pneumo-
nia in the period between January 2012 and May 2017. Age,
sex, comorbidities, clinical and laboratory variables, radiolog-
ical severity, progression and mortality were analyzed. Com-
parative analysis between HIV-positive and -negative patients
was carried out. Receiver operating curves (ROC) for CURB-
65 were performed to predict mortality in both groups. We
included 107 patients (21 HIV-positive and 86 HIV-negative).
HIV patients were on average younger (38 vs 58 years) with
lower hematocrits (31.7 vs 36.5%) and fewer comorbidities
(47 vs 72%). Overall mortality was 36 percent, and the area
under the curve (AUC) of the CURB-65 ROC was 0.69 (95%
confidence interval: 0.58–0.79) for all patients without differ-
ences between the two groups. Patients with a history of HIV
infection had the same progression and mortality as the group
of patients without that background.
Introduction
Streptococcus pneumoniae is the main causative agent of
pneumonia, with a 10 to 25 percent rate of isolation in
blood cultures. Attributed mortality is 15 to 26 percent,
which remains high despite improvements in health
care, including the availability of intensive therapy, ef-
fective antibiotics, and specific vaccines.[1–3]
There are risk factors that predispose the development
of pneumococcal pneumonia, such as smoking, socioe-
conomic status, age, immune status, genetic suscepti-
bility, and geographic location.[2, 4] Additional factors
associated with invasive infection, such as myeloma,
immunosuppression, cerebrospinal fluid fistulas and
intravenous drug use, have also been described.[2, 5]
However, there are still controversies regarding the
prognostic impact of a history of human immunode-
ficiency virus (HIV) infection, which is especially rel-
evant considering that pneumonia is a frequent com-
plication in this group of patients despite antiretroviral
therapy. The objective of the present work was to ana-
lyze and compare the outcomes of pneumococcal bac-
teremic pneumonia in HIV-positive and -negative pa-
tients.
Methods
We retrospectively analyzed patients older than 18
years with clinical and radiological findings compati-
ble with pneumonia and isolation of S. pneumoniae in
blood cultures in the period between January 2012 and
May 2017 in a single center in Buenos Aires, Argentina.
Blood cultures were drawn at emergency admission
and incubated according to standardized lab tech-
nique. Identification of microbial agents and suscep-
tibility studies were performed according to conven-
tional methods. All patients were tested for HIV in-
fection.
Age, sex, comorbidities, clinical and laboratory vari-
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ables, radiological severity, evolution (length of hospi-
tal stay, need for ICU admission) and mortality during
hospitalization were observed. A comparative analy-
sis was conducted between HIV-positive and -negative
patients.
Statistical analysis
The results of the normally distributed quantitative
variables were expressed as means (± standard devi-
ations) and those not normally distributed were ex-
pressed as medians and interquartile ranges. Qualita-
tive variables were expressed as percentages. Normally
distributed data were compared using Student’s t-test
and chi-squared tests were applied for differences in
proportions. P-values <0.05 were considered statisti-
cally significant. CURB-65 score was used to build re-
ceiver operating curves (ROC) for mortality, and mul-
tiple logistic regressions were used to test for the pres-
ence of confounders.
The data was analyzed with the statistical analysis soft-
ware STATA 13 (StataCorp. 2013. Stata Statistical Soft-
ware: Release 13. College Station, TX: StataCorp LP)
The work was approved by the Hospital Ethics Com-
mittee (ref. 242 - Code LUPOSO/19).
Results
We analyzed 107 patients with community-acquired
pneumonia and isolation of S. pneumoniae in blood cul-
tures. Twenty-one patients were HIV-positive. The av-
erage age was 54 years (±17.37); 40% were women and
31% were admitted to the intensive care unit. The av-
erage onset of symptoms was 6.3 days (± 6.75) before
the consultation. The most frequent comorbidities were
smoking (39%), alcoholism (20%), diabetes (17%) and
cancer (17%). Radiological involvement of two or more
lobes was observed in 43% of patients and the pres-
ence of a pleural effusion in 25% of cases. Regarding
the laboratory tests performed at admission, the means
were: PaO2/FiO2 279 (± 106 standard deviation (SD)),
urea 0.69 mg/dL (± 0.42 SD), creatinine 1.67 mg/dL (±
1.24 SD), sodium 133 meq/L (± 6 SD) and glucose 149
mg/dL (± 102.35 SD). The proportions of patients in
each CURB-65 group were: 13% for group 0, 32.7% for
group 1, 26.17% for group 2, 16.82% for group 3, 9.35%
for group 4 and 1.87% for group 5. The mean age of
HIV-positive and -negative patients was 38 vs 58 years,
and HIV-positive patients had lower hematocrits (32%
vs 37%) and fewer comorbidities (47 vs 72%). Table 1
shows patient characteristics for the study population
on the day of admission.
Overall mortality was 36%; mortality was higher in
CURB-65 4 and 5, where it reached 75%. No differences
between these two groups was observed. The mean
length of hospitalization was 11 days (±11.41). Table
2 shows outcomes for the study population.
ROC of CURB-65 score was performed to predict global
mortality. The overall area under the curve (AUC) was
0.69 (95% confidence interval (CI): 0.58–0.79): 0.71 (95%
CI: 0.60–0.83) and 0.67 (95% CI: 0.47–0.87) for the HIV-
negative and -positive groups, respectively, with no
statistically significant difference (P=0.68) (Figure 1).
In the HIV-positive group, the median CD4 count was
71 cells/mm3 (interquartile range: 272). The strains
that presented resistance to oxacillin had an MIC <4
for penicillin, and 11% were resistant to macrolides. All
isolates were sensitive to levofloxacin.
Discussion
Lung infections in HIV patients are a common cause
of morbidity and mortality, being 25 times more fre-
quent than in the general population. Antiretroviral
therapy (ART) reduces opportunistic infections; how-
ever, bacterial pneumonia remains prevalent.[6–8] The
evolution and prognosis in this group of patients are
controversial. Feldman et al. compared a group of HIV-
positive patients with bacteremic pneumonia with an
HIV-negative group, noting that HIV-positive patients
had higher 14-day mortality and an increasing trend
in mortality with lower CD4 levels.[9] Similarly, other
studies found worse prognosis in HIV-positive patients
with bacteremia.[10, 11] Factors associated with high
mortality have been described, such as Karnofsky score
<50, neutropenia, CD4 count <100 cells/mm3, Po2 <70
mmHg, septic shock, and radiological progression.[12]
In other studies, the mortality rates of bacteremic pneu-
monia in patients with a history of HIV are similar to
the control groups; however, these results may be re-
lated to high CD4 values in the cohorts studied.[1, 13,
14] In a study by Bordón et al. that included 117 pa-
tients, the evolution and prognosis were not found to
be related to CD4 values or HIV-RNA levels.[15]
In our study, some significant differences were ob-
served in the population of patients with and without
HIV: HIV-positive patients were younger with lower
hematocrit values and lower percentages of comorbidi-
ties. However, in both groups, the values of CURB-65 4
and 5, mortality, radiological compromise, presentation
and clinical progression were similar even after adjust-
ing for the differences mentioned above.
The state of immunodeficiency in patients with HIV in-
cluded in our study (in which the median CD4 count
was 71) was not associated with worse outcomes in
terms of clinical progression and mortality.
Regarding the length of hospital stay and the time to
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/17 2
ULJRI Pneumococcal Pneumonia in HIV Patients
Table 1. Patient characteristics for the study population on the day of admission.
HIV infection No HIV infection P
Study population, n 21 86
Demographics
Age years (±SD) 38 (±13.53) 58 (±16.14) 0.002
Male sex, n (%) 15 (71.43) 50 (58.14) 0.264
Social and Medical History
Diabetes mellitus, n (%) 1 (4.76) 17 (19.77) 0.189
Current or former smoker, n (%) 8 (38.1) 35 (40.7) 0.827
Congestive heart failure n (%) 0 5 (5.81) 0.581
Obesity (BMI ≥ 30) n (%) 0 4 (4.65) 0.584
Chronic renal failure n (%) 1 (4.76) 8 (9.30) 0.685
Chronic obstructive pulmonary disease n (%) 0 6 (6.98) 0.595
Neoplastic disease n (%) 0 20 (23.26) 0.011
Physical Exam Findings
Systolic blood pressure (mmHg) 100 (±19.52) 104 (±25.3) 0.433
Diastolic blood pressure (mmHg) 58 (±11.52) 63(±15.84) 0.211
Heart rate (beats/minute) 104 (±21.92) 103 (±19.94) 0.828
Respiratory rate (breaths/minute) 24 (±5.59) 25 (±6.31) 0.642
Temperature (°C) 37.35 (±1.21) 37.14 (±1.23) 0.489
Pleural effusion n (%) 2 (9.5) 25 (29) 0.09
Laboratory Findings
Serum sodium (mEq/L) 133 (±5.30) 133 (±6.25) 0.91
Serum glucose (mg/dL) 113 (±66.51) 158 (±107.59) 0.07
Hematocrit (%) 31.73 (±5.22) 36.56 (±6.78) 0.003
Leukocytes cells/mL) 13,395 (±9700) 22,078 (±12725) 0.19
Urea (mg/dL) 0.55 (±.34) 0.72 (±.43) 0.09
Creatinine (mg/dL) 1.4 (±1.03) 1.21 (±1.29) 0.28
Severity of disease on admission
CURB-65 score 4 or 5 1 (5.56) 11 (13.1) 0.36
Altered mental status 4 (20) 24 (28.4) 0.58
PaO2/FiO2 262 (±111) 282 (±105) 0.49
ICU Admission 6 (28.5) 27 (31.4) 0.8
Mechanical ventilation 4 (20) 20 (23.2) 1
Vasopressor use 4 (20) 24 (27.9) 0.58
CXR with ≥2 lobes 12 (57.1) 34 (40.4) 0.16
Data are presented as n (%) or mean (±SD).
BMI: body mass index; CXR: chest X-ray; SD: standard deviation.
Table 2. Outcomes for the study population.
HIV infection No HIV infection P
Study population (n) 21 86
Mean length of stay (days) (±SD) 9.14 (±6.59) 12.35 (±12.3) 0.25
Mortality n (%) 9 (42.8) 30 (34.8) 0.49
SD: standard deviation
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Figure 1. Comparative ROC for CURB-65 for both groups of patients.
ROC: receiver operating curve.
clinical stability, there are also controversies with re-
spect to HIV-positive patients with pneumonia. Ma-
linis et al. analyzed 118 patients with HIV and found
no differences in time to clinical or hospital stability.
Christensen et al. analyzed 58 HIV-positive patients
diagnosed with pneumonia, compared them with 174
HIV-negative patients and found similar results.[13, 14]
In the latter study, length of hospital stay did not show
statistically significant differences either.
On the other hand, the mortality rate of community-
acquired pneumonia with bacteremia varies among
different reports; this could be due to the different
study populations.[16] Several authors have found that
bacteremia is a risk factor for mortality. A meta-
analysis identified 11 risk factors for associated mortal-
ity, which included bacteremia.[17] Garcı́a-Vidal et al.
also identified bacteremia as an independent risk fac-
tor for mortality.[18] Capelastegui et al. compared 492
patients with negative blood cultures and 399 with pos-
itive cultures; bacteremia had a worse evolution (more
days of hospitalization, high rates of mechanical respi-
ratory support and shock) and greater in-hospital mor-
tality at 15 and 30 days.[19] Similar results were ob-
served in the study by Bordón et al.[10] Musher et al.
and Kang et al. describe 29% mortality.[20, 21] Other
studies concluded that the severity index CURB-65 and
PSI are higher in patients with bacteremia.[19, 22]
By contrast, other authors find a poor correlation
between bacteremia and the severity of the symp-
toms.[23] Marrie et al., in a multicenter study, found
no differences in mortality, but an adjusted analysis
was not performed, and severe patients were not in-
cluded.[24] Another multicenter study carried out by
Bordón et al. concluded that patients with bacteremia
do not have a worse evolution.[25] Amaro et al. de-
scribed 917 patients with pneumonia due to pneumo-
coccus, of whom 362 presented bacteremia; greater
severity and length of stay were observed in the group
with bacteremia but with the same mortality.[26] In the
work of Palma et al. and Cillóniz et al., no differences
were found in mortality or hospitalization time.[1, 27]
In our cohort of patients, the mortality rate was higher
than those reported in the literature. However, it is
not possible to correlate this with the presence of bac-
teremia since it exceeds the purpose of the present
study.
With regard to the limitations of our work, the cohort of
patients studied was from a single center and, we did
not have data related to the use of antiretroviral treat-
ment or on prior antipneumococcal vaccination.
Our work shows that HIV patients with bacteremic
pneumococcal pneumonia do not differ in evolution
and mortality compared to patients without this back-
ground, as suggested by other authors.
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